Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449903 | 0.84 | NR1H2 (0.47) | NR1H2NR1H3HPGDSDGAT1SMN1; SMN2 | |
| SCHEMBL6448692 | 0.84 | NR1H2 (0.44) | NR1H2NR1H3HPGDSDGAT1SMN1; SMN2 | |
| SCHEMBL6453081 | 0.80 | SMN1; SMN2 (0.44) | NR1H2NR1H3HPGDSDGAT1SMN1; SMN2 | |
| SCHEMBL6454208 | 0.80 | TRPV1 (0.39) | TRPV1NR1H2NR1H3DGAT1SMN1; SMN2 | |
| SCHEMBL6454148 | 0.80 | SMN1; SMN2 (0.53) | TRPV1NR1H2NR1H3DGAT1SMN1; SMN2 | |
| SCHEMBL6457945 | 0.79 | RAB9A (0.57) | NR1H2NR1H3HPGDSDGAT1SMN1; SMN2 | |
| SCHEMBL6448731 | 0.77 | NR1H2 (0.56) | TRPV1NR1H2NR1H3 | |
| SCHEMBL6450407 | 0.76 | FEN1 (0.43) | NR1H2NR1H3HPGDSDGAT1SMN1; SMN2 | |
| SCHEMBL6451202 | 0.75 | MAPT (0.53) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6453884 | 0.75 | TRPV1 (0.44) | TRPV1NR1H2NR1H3SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | TRPV1 1359/4885NR1H2 34/4885NR1H3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.